Condition: Urothelial Bladder Cancer · Sponsor: Pacific Edge Limited
Surveillance for recurrence of urothelial carcinoma (UC) requires frequent cystoscopy, which is invasive, expensive and time-consuming. An accurate urinary biomarker has the potential to reduce the number of cystoscopies required during post-treatment surveillance. This is a prospective, single arm, multi-center study using the diagnostic CxBladder test with subjects previously diagnosed with primary or recurrent UC and who are undergoing a schedule of investigative cystoscopies and treatment for the possible recurrence of UC presenting to qualified sites. To evaluate the performance characteristics of the CxBladder test, multiple consecutive urine samples will be collected during the course of surveillance.
This description comes directly from the study's public registry record.
Donna Smith, MSc (Hons) · +64 21 243 6696 · donna.smith@pacificedgedx.com
Alexis White · +64 21 959 001 · alexis.white@pelnz.com
Always discuss trial participation with your own doctor first.
| Miami VA Healthcare System | Miami, Florida, United States | Recruiting |
| James A. Haley Veteran's Hospital | Tampa, Florida, United States | Recruiting |
| Ralph H. Johnson VA Health Care System | Charleston, South Carolina, United States | Recruiting |
| UT Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| White River Junction Veterans Affair Medical Center | White River Junction, Vermont, United States | Recruiting |
| University of Washington School of Medicine | Seattle, Washington, United States | Recruiting |
| Monash Health - Moorabbin Hospital | Clayton, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05080998